Thursday, 2 December 2021

Australia's most trusted
source of pharma news

Thursday, 02 December 2021

Sell-off talk again hits Sandoz

Posted 27 October 2021 PM

With generics subsidiary Sandoz dragging on the performance of Novartis the pharmaceutical giant is again looking at shedding the division, undertaking a "strategic review" into which options maximise value.

In its third quarter results Novartis reported net sales growing five per cent year-on-year in constant currency. Its Innovative Medicines division grew seven per cent, but the generics division Sandoz declined two per cent due to ongoing pricing pressures.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.